Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis

This is an interventional treatment trial for Cerebral Atherosclerosis Read More

Inclusion Criteria:

1. Patients of both genders aged 40-75 years old inclusive.

2. Diagnosis of cerebral atherosclerosis verified by all three signs:

   • underlying vascular disease (atherosclerosis and/or hypertension) and focal neurological symptoms combined with cerebral symptoms (headache, dizziness, tinnitus, impaired memory, working capacity);
   • ultrasound signs of atherosclerotic cerebrovascular lesions (according to MAH duplex scanning within 6 months preceding the patient enrollment into the study);
   • signs of morphological changes in the brain based on neuroimaging (CT/MRI 1.0-1.5 T) (subcortical and periventricular leukoaraiosis and/or focal changes in grey matter and white matter in the form of postischemic cysts and/or lacunar strokes and/or diffuse atrophic changes in the form of dilated cardiovascular system or subarachnoidal spaces).
3. Cognitive disorders (MoCa <26).
4. Patients with unchanged dose and combination of basic therapy of cerebral atherosclerosis and hypertension during the previous month.
5. Patients who gave their consent to use reliable contraception during the study.
6. Availability of signed patient information sheet and informed consent form for participation in the clinical trial.

Exclusion Criteria:

1. History of subarachnoidal/parenchymatous/ventricular hemorrhage, cerebral tumour or another disease resulting in neurological disorders.
2. Ischemic-type stroke or any other acute cerebrovascular accident less than 6 months prior to the study with Modified Rankin Scale (mRs) > 1 .
3. Cardiac sources of high risk or medium risk embolism (TOAST criteria).
4. Signs of acute or exacerbated chronic infectious diseases at or less than 2 weeks prior to screening.

5. History of CNS diseases including:

   • Inflammatory CNS diseases (G00-G09)
   • Systemic Atrophies Primarily Affecting the CNS (G10-G13)
   • Other degenerative diseases of the nervous system (G30-G32)
   • Demyelinating diseases of the CNS (G35-G37).
6. Dementia (F00-F03).
7. Previously diagnosed cardiovascular diseases with functional class III or IV (according to New York Heart Association, 1964).
8. Hypothyroidism, diabetes mellitus and other somatic diseases at decompensation stage.
9. Uncontrollable hypertension: SBP > 180 mm Hg and/or DBP > 110 mm Hg.
10. Diseases of lower limb veins (lower limb varicose veins, deep venous thrombosis, etc.) at decompensation stage.
11. Any other severe concomitant pathology which, according to the investigator, may interfere with the patient's participation in the study.
12. History/suspicion of oncology of any location (except for benign neoplasms).
13. Allergy/intolerance of any component of the drug products used in the therapy.
14. Hereditary lactose intolerance.
15. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any other disaccharidase deficiency) and galactosemia.
16. Pregnancy, breast-feeding.
17. History of treatment non-compliance, psychiatric disorders, alcoholism or drug abuse which, according to the investigator, may interfere with the study procedures.
18. Use of any medicine indicated in the section "Prohibited concomitant treatment" within 1 month prior to enrollment.
19. Participation in other clinical trials in the previous 3 months.
20. Patients who are related to any of the on-site research personnel directly involved in the study or are an immediate relative of the study investigator, or has another conflict of interests. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).
21. Patients who work for OOO "NPF "MATERIA MEDICA HOLDING" (i.e. the company's employees, temporary contract workers, appointed officials responsible for carrying out the research or immediate relatives of the aforementioned).